Spleen stiffness test for PBC patients
Part of Digestive system clinical trials.
This trial uses a non-invasive scan to measure spleen stiffness in people with primary biliary cholangitis (PBC). It aims to see if this measurement can help track disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- You are being treated for PBC with ursodeoxycholic acid and/or bezafibrate
- You are an outpatient at UZ Brussels
- You do not have ascites (fluid in the belly) or advanced heart failure that would prevent a liver/spleen scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ultrasound method that measures spleen stiffness to help diagnose swollen veins in the esophagus (called esophageal varices) in people with chronic liver disease. If these veins are found early, it could help prevent dangerous bleeding.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This trial uses a non-invasive ultrasound test to measure spleen stiffness, which may help find problems with blood pressure in the liver and identify enlarged veins that can bleed. It could help avoid more invasive tests.
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
This trial uses a simple ultrasound test (measuring liver and spleen stiffness) to predict if a patient with cirrhosis and advanced liver cancer has enlarged veins in the esophagus. The goal is to avoid unnecessary invasive procedures like endoscopy.
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.